一分钟看懂
这是一项关于晚期实体瘤的I 期 / II 期研究，登记的药物或干预包括BNT326；Pumitamig；Itraconazole；Paroxetine，当前状态为招募中。登记地点显示中国杭州、天津、武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BNT326；Pumitamig；Itraconazole；Paroxetine · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine · 杭州
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Hubei Cancer Hospital · 武汉
公开的入选条件
- (applicable to all participants and all parts unless otherwise specified):
- * Aged ≥18 years at the time of giving informed consent. Local laws will be followed if the age of consent is older.
- * Have histologic or cytologic documented advanced disease, either at relapse or upon diagnosis of metastatic disease. This requirement may be considered met when advanced disease derives from unequivocal progression of a previously biopsied site of disease (e
- * Have measurable disease defined by RECIST v1.1.
- * Have ECOG performance status of 0 or 1.
- * Have adequate organ and bone marrow function (as specified in the protocol) within 7 days before randomization/enrollment.
- * Cohort 1A:
- Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07070232；登记信息更新于 2026-09-02。